As prostate cancer incidence in the US continues to decline, the overall stage distribution has shifted to an increasing proportion of distant diagnoses following declines in PSA test use.37 Additional years of data are needed to determine whether the US fatal prostate cancer incidence rate will continue to decline and stabilise. The gene discussed is KLK3; the disease is prostate carcinoma.